Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financi... (Condensed Consolidated Balance Sheets .....)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results

Date:3/13/2008

Condensed Consolidated Balance Sheets

(In thousands, except par value)

December 31, December 31,

2007 2006

Assets

Current assets:

Cash and cash equivalents $27,066 $24,301

Accounts receivable 4,689 2,319

Prepaid expenses and other current assets 2,579 2,048

Total current assets 34,334 28,668

Property and equipment, net 4,390 3,357

Goodwill 6,462 6,917

Patents, net 7,680 8,850

Other assets 196 321

Restricted cash 3,190 3,059

Total assets $56,252 $51,172

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable $2,335 $1,680

Accrued expenses 4,765 10,153

Warrant liabilities 5,218 -

Other liabilities 520 366

Short-term note - 1,320

Current portion of long-term debt obligations 2,401 599

Current portion of deferred revenue 3,360 2,972

Total current liabilities 18,599 17,090

Deferred revenue, net of current portion 8,366 195

Other non-current liabilities 2,055 1,961

Long-term debt obligations, net of current

portion
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007

Post Your Comments:

Breaking Biology Technology:Biomatrica Launches SampleWare 3.1 2 Biomatrica Launches SampleWare 3.1 3 Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 2 Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 3 New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2 New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3 Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2

[0] Biomatrica Launches SampleWare 3.1 [0] Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors [0] New silicon-germanium nanowires could lead to smaller, more powerful electronic devices [0] Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease

Other Biology Technology:Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer 2 Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer 3 Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer 4 Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer 5 Plurality Completes R&D of its HAL-256 Multicore Processor 2 NIU Seeks OK for New Proton Cancer Treatment and Research Center 2 NIU Seeks OK for New Proton Cancer Treatment and Research Center 3

Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer Plurality Completes R&D of its HAL-256 Multicore Processor NIU Seeks OK for New Proton Cancer Treatment and Research Center

Breaking Biology News(10 mins):Newly discovered mechanism allows cells to change state 2 BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 1 BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 2 BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 3 BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 4 New Drug Promising Against Rheumatoid Arthritis 50263 1 New Drug Promising Against Rheumatoid Arthritis 50263 2 Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 1 Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 2 Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 3

[0] New clues emerge for understanding morphine addiction [0] Newly discovered mechanism allows cells to change state [0] UBC geneticist reveals molecular view of key epigenetic regulator

Other Biology News:Brown University and Women & Infants Hospital expand national children's study to Bristol County 2 Brown University and Women & Infants Hospital expand national children's study to Bristol County 3 Brown University and Women & Infants Hospital expand national children's study to Bristol County 4 The structure of the Mre11 protein bound to DNA 2 The structure of the Mre11 protein bound to DNA 3 The structure of the Mre11 protein bound to DNA 4 The structure of the Mre11 protein bound to DNA 5 The structure of the Mre11 protein bound to DNA 6 UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome 2 UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome 3

Brown University and Women & Infants Hospital expand national children's study to Bristol County The structure of the Mre11 protein bound to DNA UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome

Biology Products:

Rabbit Anti-Human ROR Gamma Antibody, Unconjugated from ABR-Affinity BioReagents GIBCO Leibovitz's L-15 Medium powder from Invitrogen BioPrime Array CGH Genomic Labeling Module from Invitrogen GIBCO Improved MEM Zn++ Option (Richter's Modification) liquid from Invitrogen